Last reviewed: June 25, 2026

Last updated: June 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide eligibility standards have expanded significantly since the medication's initial FDA approval for type 2 diabetes in 2017. Today, this GLP-1 receptor agonist helps millions of adults manage weight and metabolic health, but specific medical and physical criteria determine who benefits most from treatment. Understanding your eligibility starts with knowing the established guidelines and how your individual health profile aligns with evidence-based recommendations.

BMI Thresholds and Weight-Based Semaglutide Eligibility

Body mass index forms the foundation of semaglutide eligibility assessment for weight management. Adults with a BMI of 30 or higher generally qualify for semaglutide therapy, while individuals with a BMI between 27 and 29.9 who also have weight-related health conditions such as high blood pressure, type 2 diabetes, or cardiovascular disease may also be candidates. These thresholds reflect clinical trial populations that demonstrated significant weight reduction and health improvements across diverse body compositions.

BMI calculations alone do not capture your complete metabolic picture. Factors including waist circumference, muscle mass distribution, and insulin resistance status influence how your body responds to GLP-1 therapy. PlexusDx evaluates these elements during the initial consultation to ensure semaglutide aligns with your specific health needs rather than relying solely on a single measurement.

Medical Conditions and Comorbidities Supporting Semaglutide Use

Type 2 diabetes diagnosis strengthens semaglutide eligibility, as this indication has the longest safety and efficacy data from multiple large-scale trials. However, semaglutide benefits extend to patients without diabetes who struggle with weight management complicated by conditions like hypertension, dyslipidemia, sleep apnea, or nonalcoholic fatty liver disease. Each comorbidity represents a potential therapeutic target where GLP-1 receptor activation provides metabolic advantages beyond appetite suppression.

Cardiovascular health status influences semaglutide candidacy significantly. Patients with existing coronary artery disease, heart failure, or a personal history of stroke have demonstrated cardiovascular benefits from semaglutide therapy in landmark studies. Conversely, certain cardiac conditions require careful medical supervision during treatment initiation, making professional clinical assessment essential before starting any GLP-1 medication.

Age, Kidney Function, and Safety Considerations for Eligibility

Semaglutide eligibility generally applies to adults aged 18 and older, though safety data in older populations remains reassuring across multiple trials. Kidney function assessment determines whether dose adjustments or closer monitoring becomes necessary, as GLP-1 medications undergo partial renal metabolism. PlexusDx requires current metabolic panel results showing creatinine and eGFR values before treatment initiation to ensure safe dosing protocols.

Gastrointestinal history influences semaglutide candidacy because GLP-1 agonists slow gastric emptying and may exacerbate symptoms in patients with severe reflux disease, gastroparesis, or inflammatory bowel conditions. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) represents a contraindication to semaglutide use. Transparent discussion of your complete medical history during the initial evaluation enables PlexusDx clinicians to identify any exclusion factors.

How PlexusDx Determines Individual Semaglutide Eligibility

PlexusDx streamlines eligibility assessment through a comprehensive intake process combining medical history review, current medication inventory, and metabolic screening. Licensed clinicians evaluate your unique combination of weight, comorbidities, medication interactions, and kidney function to determine whether semaglutide represents an appropriate first-line option or whether alternative GLP-1 compounds like tirzepatide might better address your specific health profile. This personalized approach goes beyond checkbox eligibility to optimize therapeutic outcomes.

The Precision Peptide Genetic Test available through PlexusDx adds another dimension to eligibility optimization by mapping 14 metabolic pathways and analyzing genetic variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) that influence medication response. Understanding your genetic predispositions enables clinicians to predict which patients achieve superior weight loss and metabolic improvements with semaglutide specifically. PlexusDx integrates genetic insights with clinical data to deliver truly precision-guided treatment decisions available nationwide starting at $149 per month.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What BMI do I need to qualify for semaglutide treatment at PlexusDx?

A BMI of 30 or higher generally qualifies you for semaglutide weight management therapy. If your BMI falls between 27 and 29.9, you may still qualify if you have weight-related comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease. PlexusDx clinicians evaluate your complete health profile during consultation to confirm eligibility regardless of BMI alone.

Can I get semaglutide if I don't have type 2 diabetes?

Yes. Semaglutide eligibility extends to adults without diabetes who meet BMI thresholds or who have weight-related health conditions complicated by metabolic dysfunction. Clinical trials have demonstrated significant cardiovascular and weight reduction benefits in non-diabetic populations, making semaglutide an appropriate option for many patients seeking sustainable weight management.

Does PlexusDx require insurance or membership fees for semaglutide?

No insurance is required, and PlexusDx charges no membership fees. Compounded semaglutide injections start at $149 per month across all 50 states and are HSA/FSA eligible. Your dose may need to increase during treatment. Your price won't.

What kidney function levels affect semaglutide eligibility?

Semaglutide remains appropriate for most patients across kidney function ranges, though monitoring becomes important with moderate to severe renal impairment. PlexusDx requires current creatinine and eGFR results before starting treatment to ensure safe dosing protocols. Patients with eGFR below 15 require careful medical supervision and may need dose modifications.

How does the Precision Peptide Genetic Test improve my semaglutide eligibility assessment?

PlexusDx Precision Peptide Genetic Test ($99 add-on after your first treatment month) analyzes genetic variants in GLP1R, GIPR, FTO, and MC4R that influence your individual response to semaglutide. This test maps 14 metabolic pathways and 49 peptides to predict which patients achieve optimal weight loss and health improvements, personalizing your treatment approach beyond standard eligibility criteria.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves